SCHEMBL2114073

SCHEMBL2114073

COc1cc(C(=O)O)c2c(c1C)OC(=O)c1c(C)cc(O)c(C=NNC(=O)c3cccc(F)c3)c1O2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.53
MEN1 O00255 6/20 0.53
KDM4E B2RXH2 4/20 0.53
MAPT P10636 3/20 0.53
LMNA P02545 3/20 0.53
ALDH1A1 P00352 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
HPGD P15428 1/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 3/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
APAF1 O14727 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
SERPINE1 P05121 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114548 0.88 MEN1 (0.55) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2113567 0.85 KDM4E (0.56) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2113902 0.84 MAPT (0.54) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2113128 0.82 MEN1 (0.60) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2112670 0.81 MEN1 (0.67) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2112673 0.81 MEN1 (0.67) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2114070 0.80 ALDH1A1 (0.55) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2114074 0.80 ALDH1A1 (0.55) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2111335 0.78 MAPT (0.55) KMT2AMEN1KDM4EMAPTLMNA
SCHEMBL2111333 0.78 MAPT (0.55) KMT2AMEN1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
EP-2199295-A1 COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2010-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME GPR119, CYP11B1, HSD11B1 KMT2A 4629/4885MEN1 730/4885KDM4E 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.